Knight Therapeutics Inc. GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 396.13M | 369.53M | 322.69M | 296.41M | 275.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 396.13M | 369.53M | 322.69M | 296.41M | 275.81M |
| Cost of Revenue | 208.50M | 199.80M | 179.05M | 170.37M | 157.28M |
| Gross Profit | 187.62M | 169.73M | 143.64M | 126.04M | 118.53M |
| SG&A Expenses | 99.54M | 93.36M | 86.46M | 79.11M | 75.27M |
| Depreciation & Amortization | 41.56M | 39.59M | 35.50M | 33.17M | 30.15M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 377.02M | 357.08M | 321.81M | 302.09M | 279.61M |
| Operating Income | 19.11M | 12.45M | 884.70K | -5.68M | -3.80M |
| Income Before Tax | 15.48M | 5.72M | -4.90M | -7.33M | -5.49M |
| Income Tax Expenses | 4.71M | 1.64M | -899.50K | -4.64M | -5.62M |
| Earnings from Continuing Operations | 10.77 | 4.08 | -4.00 | -2.68 | 0.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.77M | 4.08M | -4.00M | -2.68M | 130.90K |
| EBIT | 19.11M | 12.45M | 884.70K | -5.68M | -3.80M |
| EBITDA | 62.01M | 53.29M | 37.99M | 30.79M | 29.59M |
| EPS Basic | 0.11 | 0.04 | -0.04 | -0.03 | 0.00 |
| Normalized Basic EPS | 0.12 | 0.06 | -0.02 | -0.03 | -0.03 |
| EPS Diluted | 0.11 | 0.04 | -0.05 | -0.04 | -0.01 |
| Normalized Diluted EPS | 0.12 | 0.06 | -0.02 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 395.65M | 397.08M | 398.27M | 399.46M | 400.94M |
| Average Diluted Shares Outstanding | 396.65M | 398.08M | 399.23M | 400.31M | 401.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |